Q3 2026 OrthoPediatrics Corp. Earnings Conference Call - ORTHOPEDIATRICS CORP

Explicit Guidance:

• FY 2026 Revenue: Raised to $270–$273 million, implying 14–16% year-over-year growth.
• FY 2026 Adjusted EBITDA: Reiterated at approximately $25 million.
• FY 2026 CapEx/Set Deployment: Expected to deploy approximately $10 million in instrument sets.
• FY 2026 Free Cash Flow: Guidance to be breakeven or better.
• FY 2027 Free Cash Flow: Projected to be positive.
• Q4 2026 Margin: Management anticipates gross margin to settle at approximately 73% for the quarter.

Business-Segment Outlook:

• Trauma & Deformity: Driven by share gains in legacy portfolios (cannulated screws, PMP femur) and super-cycle products (3P Hip, PD plates). 3P Hip is in full commercial launch; 3P Small and 3P Mini expected to move to full market release in the first half of 2027. PMP Retrograde limited launch successful in late 2026, with full commercialization planned for mid-2027.
• Scoliosis: Expected to see strong growth in 2027 driven by the "super cycle" products, specifically VertiGlide (moving to full commercial release) and the upcoming limited release of the next-generation fusion system, Varaxis.
• Ellie (Electromechanical Growing Implant): First inpatient procedures expected in early 2027 pending FDA IDE approval; expected to be a larger revenue opportunity than VertiGlide but ramping into 2028–2029 rather than 2027.
• OPSB (Orthopedic Specialty Bracing): Growth rate above 20% expected to continue. Portfolio includes full market release of PD-HIP Rigid Brace (HIPPO) and limited launch of Knee Tractor Fix. Clinic footprint expanded to >60 clinics; target of 27 territories by end of 2027 appears "well ahead" of schedule with potential for further acceleration.
• International (EMEA/LAT-SAM): EMEA expected to see strong growth in 2027 as EU MDR approvals for legacy products (particularly scoliosis) roll out. LAT-SAM headwinds regarding set sales timing expected to be managed conservatively. OSSEo partnership remains focused on the U.S. market; no immediate international distribution plans.

Market and Competitive Outlook:

• Demand Trends: Pediatric orthopedic procedural volumes remain "very healthy" with no expected headwinds in Q4 2026 or 2027.
• Pricing & Contracts: Strong negotiating power anticipated as "super cycle" products with higher ASPs and superior clinical outcomes pull through legacy products (e.g., cannulated screws, flexible nails). Goal to convert simple pricing contracts into single or high dual-vendor agreements (50–80% market share) without requiring additional set deployment.
• Product Economics: New products (e.g., DF2, 3P Hip) offer higher ASPs, better margins, and capital efficiency compared to legacy sets. OPSB products (e.g., DF2) have high ASPs, nice margins, and require no inventory consignment.
• Adoption Curves: DF2 expected to become ubiquitous in U.S. children's hospitals within a few years; adoption driven by clinical superiority over spica casting.

Macro / Industry Outlook:

• Regulatory Environment: Continued reliance on FDA approvals (e.g., PMP Retrograde, Ellie) as primary gatekeepers for product launches. EU MDR approvals are successfully unlocking international growth for legacy scoliosis and bracing products.
• Seasonality: Q4 2026 is expected to be strong but conservative guidance accounts for potential absence of large set sales (e.g., Brazil 70-unit sale in Q4 2025) and timing of distributor commissions (clawbacks).

Strategic Initiatives:

• Product Launches:
  • 3P Platform: 3P Hip (full launch) -> 3P Small/Mini (H1 2027 full launch).
  • PMP Platform: PMP Retrograde limited launch (Q4 2026) -> Full commercialization (mid-2027).
  • Bracing: PD-HIP Rigid Brace (full release), Knee Tractor Fix (limited launch).
  • Scoliosis: VertiGlide (expanding adoption), Varaxis (next-gen fusion system, beta/limited launch in 2027).
  • OSSEo: Bio-integrative technologies expanding portfolio; no immediate international rollout planned.
• Clinic Expansion: Rapidly expanding footprint to >60 clinics; balancing greenfield growth with profitability and personnel capacity.
• Capital Deployment: Discipline maintained on set deployment to balance growth with FCF generation; prioritizing higher-return systems.

Risks and Headwinds to Outlook:

• Set Sales Timing: Volatility in large set sales (e.g., Brazil) could impact Q4 revenue if not recurring.
• Regulatory Delays: Ellie's timing depends on FDA IDE approval and the number of required procedures for full market release.
• Expense Leverage: S&M expenses rose to 31.5% of sales in Q3 due to distributor kicker payments; expected to revert in Q4, but future growth investments (clinic expansion) may sustain higher absolute spend.
• Cash Flow Constraints: "Tug of war" between aggressive set deployment for growth and the mandate to remain FCF positive.
• International Headwinds: LAT-SAM performance may be tempered by AR balance management and restricted set sales in specific markets like Brazil.

Management Tone on the Future:

• Confidence Level: High confidence in the multi-year "super cycle" as a sustainable growth driver for revenue, margins, and capital efficiency.
• Strategic Posture: "Thoughtful" and "measured" approach to product rollouts; avoiding over-aggression in set deployment to ensure FCF breakeven in 2026 and positive FCF in 2027.
• Guidance Stance: Conservative bias in Q4 and 2027 guidance; explicitly choosing not to "bank" on one-time set sales to protect profitability targets.

Miscellaneous:

• Operational Metrics: 3P Hip moved from limited to full launch; >1,000 PNP tibial nail implantations; >125 surgeons trained on VertiGlide (with total training volume higher at local levels); DF2 adoption in nearly 50% of U.S. children's hospitals.
• Financial Composition: International revenue (~$14.8M in Q3) driven by EMEA demand for legacy scoliosis/bracing and LAT-SAM execution; ~80% of revenue from U.S. markets.
• Cost Structure: S&M increased 24% YoY in Q3 due to commissions; G&A increased 10% due to clinic expansion and stock comp; R&D increased slightly YoY.